Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
49 hedge funds and large institutions have $71.1M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 12 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
50% more capital invested
Capital invested by funds: $47.5M → $71.1M (+$23.6M)
8% less funds holding
Funds holding: 53 → 49 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.23M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$909K |
| 3 |
Renaissance Technologies
New York
|
+$871K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$327K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.01M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$1.12M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$883K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$797K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$183K |
DRNA Hedge Fund Activity: Q3 2016 in Review
49 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2016, worth a combined $71.1M — up 50% from $47.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DRNA and 8 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $1.23M. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.01M sold.
- 49 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2016, down from 53 in Q2 2016.
- Funds reported $71.1M of Dicerna Pharmaceuticals, Inc. stock for Q3 2016, up 50% quarter-over-quarter.
- 8 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2016 and 12 closed out, a net change of -4 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2016 was 683 Capital Management, an estimated $1.23M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2016 was Wellington Management Group, an estimated $2.01M sold.
Based on aggregated 13F filings for Q3 2016.